Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.59 |
| ▸ | AKT1 | P31749 | 2/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 7/20 | 0.50 |
| ▸ | CYP2E1 | P05181 | 4/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.49 |
| ▸ | CYP2B6 | P20813 | 4/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | CDK9 | P50750 | 2/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13888053 | 0.81 | MAP3K5 (0.56) | MAP3K5AKT1PDPK1CYP2E1CYP3A4 | |
| SCHEMBL3349924 | 0.81 | CYP2A6 (0.48) | MAP3K5AKT1CYP2E1CYP3A4CYP2D6 | |
| SCHEMBL858166 | 0.80 | MAP3K5 (0.54) | MAP3K5AKT1PDPK1CDK2CDK9 | |
| SCHEMBL12281270 | 0.80 | PDPK1 (0.48) | MAP3K5AKT1PDPK1CYP3A4CDK2 | |
| SCHEMBL3347541 | 0.77 | CLK1 (0.42) | MAP3K5PDPK1CYP2E1CYP3A4CYP2D6 | |
| SCHEMBL3348407 | 0.77 | JAK2 (0.52) | MAP3K5CYP2E1CYP3A4CYP2D6CYP2A6 | |
| SCHEMBL4382849 | 0.76 | AKT1 (0.55) | AKT1PDPK1CYP3A4CDK2CDK9 | |
| SCHEMBL4376699 | 0.76 | AKT1 (0.63) | MAP3K5AKT1PDPK1CYP3A4CDK2 | |
| SCHEMBL3353473 | 0.76 | SGK1 (0.44) | MAP3K5AKT1PDPK1CYP2E1CYP3A4 | |
| SCHEMBL3351252 | 0.75 | CYP2A6 (0.49) | MAP3K5AKT1CYP2E1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180370966-A1 | METHODS OF TREATMENT USING PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2018-12-27 | — | — | US | disclosed |
| US-9873693-B2 | Methods of treatment using pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873693-B2 | Methods of treatment using pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873693-B2 | Methods of treatment using pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-8778977-B2 | Pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778977-B2 | Pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8552019-B2 | Inhibitors of phosphoinositide dependent kinase 1 (PDK1) | MERCK SHARP & DOHME CORP. (US) | 2013-10-08 | — | — | US | disclosed |
| EP-2038272-B1 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2038272-B1 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20110230500-A1 | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) | MERCK SHARP & DOHME CORP. | 2011-09-22 | — | — | US | disclosed |
| WO-2010065384-A1 | INHIBITORS OF PHOSPHOINOSITIDE DEPENDENT KINASE 1 (PDK1) | MERCK SHARP & DOHME CORP. (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20100144730-A1 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHAMACEUTICALS (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144730-A1 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHAMACEUTICALS (US) | 2010-06-10 | — | — | US | disclosed |
| EP-2038272-A2 | PYRIDINONYL PDK1 INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008005457-A2 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230500-A1 | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) | PDK1, PDPK1, PDK3 | MAP3K5 68/4885AKT1 178/4885PDPK1 2/4885 |
| US-20180370966-A1 | METHODS OF TREATMENT USING PYRIDINONYL PDK1 INHIBITORS | PDK1, PDK2, PDK3 | MAP3K5 81/4885AKT1 318/4885PDPK1 6/4885 |
| US-20100144730-A1 | PYRIDINONYL PDK1 INHIBITORS | PDK1, PDK2, PDK3 | MAP3K5 91/4885AKT1 314/4885PDPK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.